rosiglitazone has been researched along with honokiol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amagaya, S; Inoue, M; Kotani, H; Mizukami, H; Tanabe, H | 1 |
| Chang, YF; Chen, HC; Chi, CW; Hsia, CY; Hsu, HT; Lee, HC; Weng, JW | 1 |
2 other study(ies) available for rosiglitazone and honokiol
| Article | Year |
|---|---|
A naturally occurring rexinoid, honokiol, can serve as a regulator of various retinoid x receptor heterodimers.
Topics: 3T3-L1 Cells; Animals; Anticarcinogenic Agents; Bexarotene; Biphenyl Compounds; Caco-2 Cells; Dimerization; Humans; Lignans; Liver X Receptors; Magnolia; Mice; Orphan Nuclear Receptors; Plant Extracts; PPAR gamma; Receptors, Calcitriol; Receptors, Cytoplasmic and Nuclear; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Signal Transduction; Tetrahydronaphthalenes; Thiazolidinediones | 2012 |
Combined effect of honokiol and rosiglitazone on cell growth inhibition through enhanced G0/G1 phase arrest in hepatoma cells.
Topics: Antineoplastic Agents, Phytogenic; Biphenyl Compounds; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; G1 Phase Cell Cycle Checkpoints; Humans; Lignans; Liver Neoplasms; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2016 |